Tags : Sintilimab

Lilly and Innovent Report the Global Expansion of their Alliance

Shots: Innovent to receive $200M up front, $825M as development and commercial milestones along with royalties on net sales of the therapy. Both the companies will retain the right to study Tyvyt in combination with other therapies as part of their own clinical programs Lilly will get an exclusive license for the therapy for geographies […]Read More

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in

Shots:sstosohShots: The P-II ORIENT-2 study involves assessing TYVYT as monothx. vs paclitaxel/ rinotecan in 190 patients in a ratio (1:1) with advanced or metastatic ESCC who failed 1L treatment The P-II ORIENT-2 resulted in meeting its 1EPs of OS with no news safety signals. The detailed results will be presented at ASCO 2020. The two […]Read More

Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination

Shots: The companies collaborated to jointly assess safety and efficacy of Chipscreen’s Chidamide in combination with Innovent’s Sintilimab + IBI305 in patients with advanced colorectal carcinoma (ACC) The focus of the agreement is to explore the combination in clinical applications of immune check-point inhibitor, angiogenesis inhibitor and epigenetic modulator in ACC  Chidamide is a HDAC […]Read More